Plasma kinetic behavior in hyperlipidemic subjects of a lipidic microemulsion that binds to low density lipoprotein

R C Maranhão1, I A Roland, O Toffoletto

  • 1Heart Institute of the Medical School Hospital (Instituto do Coração do HC-FMUSP, São Paulo, Brazil. Sadler@opus.com.br

Lipids
|June 1, 1997
PubMed

Insights

Lipoprotein-depleted emulsions (LDE) acquire apolipoproteins in plasma, mimicking low-density lipoprotein (LDL) uptake. In hypercholesterolemia, LDE clearance is slower, suggesting LDE is a valuable tool for studying lipoprotein metabolism.

Area of Science:

  • Biochemistry
  • Lipid Metabolism
  • Pharmacology

Background:

  • Lipoprotein-depleted emulsions (LDE) structurally resemble the lipid core of low-density lipoprotein (LDL).
  • LDE are hypothesized to be internalized via LDL receptors after acquiring apolipoproteins (apo) from plasma, particularly apo E.

Purpose of the Study:

  • To investigate the uptake mechanism and metabolic fate of LDE in vitro and in vivo.
  • To assess the potential of LDE as a model system for studying lipoprotein metabolism, especially in hyperlipidemic conditions.

Main Methods:

  • Assessing LDE-apo uptake kinetics and competition with LDL in mononuclear cells.
  • Investigating the binding specificity of LDE-apo by examining high-density lipoprotein (HDL) uptake.
  • Administering radiolabeled LDE to hypercholesterolemic and hypertriglyceridemic patients and healthy controls to determine plasma clearance rates.

Main Results:

  • LDE-apo exhibited saturation kinetics in mononuclear cell uptake, with an apparent K(m) of 13.1 ng protein/mL.
  • LDE-apo displaced LDL uptake (Ki = 11.5 ng protein/mL), but LDE without apo did not.
  • LDE-apo did not affect 14C-HDL uptake, indicating distinct receptor binding.
  • In hypercholesterolemic patients, LDE plasma disappearance was significantly slower (FCR = 0.02 h-1) compared to controls (FCR = 0.12 h-1).
  • In hypertriglyceridemic patients, LDE clearance was not significantly different from controls (FCR = 0.07 h-1).

Conclusions:

  • LDE, upon acquiring apolipoproteins, interacts with the LDL receptor pathway.
  • The altered plasma clearance of LDE in hypercholesterolemia highlights its utility in studying lipoprotein disorders.
  • LDE serves as a promising tool for investigating lipoprotein metabolism and receptor-mediated uptake mechanisms.

Related Concept Videos

Asymmetric Lipid Bilayer01:35

Asymmetric Lipid Bilayer

Biological membranes show uneven distribution of different types of lipids in the inner and outer layers, resulting in transverse asymmetric membranes. The treatment of the erythrocyte membrane with the enzyme phospholipase confirmed the asymmetric nature of the lipid bilayer. The enzyme hydrolyzes lipids into fatty acids and hydrophilic groups. The phospholipase acts only on the outer layer of the membrane, while the inner layer remains intact. The phospholipase treatment resulted in 80%...
Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH01:21

Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH

Drug absorption within the gastrointestinal (GI) tract is a complex process influenced by several critical factors, including the site pH, the drug's dissociation constant (pKa), and the drug's lipophilicity. The GI tract exhibits a pH gradient, with an acidic environment in the stomach and a more alkaline environment in the small intestine. This pH variation directly affects the ionization state of drugs.
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles in drug...
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...